Patents Assigned to JCR Pharmaceuticals Co., Ltd.
-
Patent number: 10759749Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.Type: GrantFiled: August 28, 2017Date of Patent: September 1, 2020Assignees: JCR Pharmaceuticals Co., Ltd., National University Corporation Kone University, National University Corporation Chiba UniversityInventors: Susumu Seino, Kenji Sugawara, Ichiro Mori, Akio Matsumoto, Yoshie Reien
-
Patent number: 10654912Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.Type: GrantFiled: September 8, 2016Date of Patent: May 19, 2020Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Kenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
-
Patent number: 10604779Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.Type: GrantFiled: March 7, 2017Date of Patent: March 31, 2020Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Shinji Kakimoto, Miroslav Matev, Tsuyoshi Fukui, Yukichi Hatano, Junya Tani, Kazutoshi Mihara, Kenichi Takahashi, Atsushi Sugimura
-
Patent number: 10557115Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in the medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in for medium.Type: GrantFiled: March 26, 2019Date of Patent: February 11, 2020Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Miroslav Matev, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
-
Publication number: 20190352599Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in said medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in said medium.Type: ApplicationFiled: March 26, 2019Publication date: November 21, 2019Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Miroslav MATEV, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
-
Publication number: 20190336586Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.Type: ApplicationFiled: December 28, 2017Publication date: November 7, 2019Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
-
Publication number: 20190338043Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: ApplicationFiled: December 26, 2017Publication date: November 7, 2019Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20190256883Abstract: Disclosed is a method for producing a glycoprotein using mammalian cells, wherein all or part of the non-reducing ends of N-glycoside binding sugar chains are mannose residues. The method is a method for producing glycoproteins using transformant mammalian cells which are prepared by introducing thereinto a ?-N-acetylglucosaminidase gene and inducing its expression.Type: ApplicationFiled: March 5, 2019Publication date: August 22, 2019Applicant: JCR Pharmaceuticals Co., Ltd.Inventor: Kenichi TAKAHASHI
-
Patent number: 10385325Abstract: Disclosed is a method for production of recombinant human alpha-galactosidase A (rh alpha-Gal A) in a large scale, with a high purity. The method comprises the steps of (a) culturing rh alpha-Gal A-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to anion-exchange column chromatography, (d) to hydrophobic column chromatography, (e) to a column chromatography employing as solid phase a material having affinity for phosphate group, (f) to cation-exchange column chromatography, (g) to dye-affinity column chromatography, and (h) to gel filtration column chromatography, in the order.Type: GrantFiled: January 21, 2016Date of Patent: August 20, 2019Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Tsuyoshi Fukui, Atsuko Kawasaki, Yukichi Hatano, Yae Ito, Kazutoshi Mihara, Atsushi Sugimura
-
Publication number: 20190225700Abstract: Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.Type: ApplicationFiled: August 25, 2017Publication date: July 25, 2019Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Yuri Koshimura, Hiroyuki Sonoda, Miroslav Matev, Shinji Kakimoto, Tsuyoshi Fukui, Yukichi Hatano
-
Publication number: 20190202781Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.Type: ApplicationFiled: August 28, 2017Publication date: July 4, 2019Applicants: JCR Pharmaceuticals Co., Ltd., National University Corporation Kobe University, National University Corporation Chiba UniversityInventors: Susumu SEINO, Kenji SUGAWARA, Ichiro MORI, Akio MATSUMOTO, Yoshie REIEN
-
Patent number: 10335439Abstract: [Problem] To provide a method for producing human corneal epithelial sheet, wherein the human corneal epithelial-derived cells obtained by culturing human corneal epithelial cells are cultured on an amnion substrate. [Solution] A method for culturing human corneal epithelial cells using mesenchymal stem cells as the feeder cells; and a method for culturing human corneal epithelial cells using a medium containing a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor and a TGF-? receptor inhibitor in various combinations.Type: GrantFiled: March 9, 2014Date of Patent: July 2, 2019Assignees: JCR Pharmaceuticals Co., Ltd., Kyoto Prefectural Public University CorporationInventors: Kiwamu Imagawa, Kenichi Maeda, Yuki Hosoda, Shuichi Yokoyama, Naoki Okumura, Noriko Koizumi, Shigeru Kinoshita
-
Patent number: 10273448Abstract: Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in the medium. Further provided are a medium comprising uridine and N-acetyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in the medium.Type: GrantFiled: November 30, 2016Date of Patent: April 30, 2019Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Miroslav Matev, Kenichi Takahashi, Shinji Kakimoto, Ayaka Kotani
-
Publication number: 20190010205Abstract: Disclosed is a medicine containing a long-lasting human growth hormone preparation as an active ingredient, which has low prolactin-like activity and shows long half-life in blood as compared with 22K human growth hormone. The long-lasting human growth hormone includes a fusion protein exhibiting growth-promoting activity and having a human serum albumin part and a 20K human growth hormone part, particularly a fusion protein in which the 20K human growth hormone part is linked to C-terminus of the human serum albumin part via a linker sequence.Type: ApplicationFiled: September 14, 2018Publication date: January 10, 2019Applicant: JCR PHARMACEUTICALS CO., LTD.Inventors: Kenichi Takahashi, Asa Yoshioka, Yuri Koshimura
-
Patent number: 10174284Abstract: [Problem] To provide, in order to manufacture cells to transplant into patients with corneal endothelial failure, a medium used to culture corneal endothelial cells obtained from human corneal tissue and grow said cells while maintaining the morphology thereof as corneal endothelial cells. [Solution] A medium containing a conditioned medium from mesenchymal stem cells; and a method in which said medium is used to culture corneal endothelial cells.Type: GrantFiled: September 5, 2013Date of Patent: January 8, 2019Assignees: JCR PHARMACEUTICALS CO., LTD., THE DOSHISHA, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Michio Hagiya, Kiwamu Imagawa, Yuuki Hosoda, Noriko Koizumi, Naoki Okumura, Makiko Nakahara, Shigeru Kinoshita
-
Patent number: 10159799Abstract: The pharmaceutical injection device includes a pharmaceutical syringe mounting portion (3) provided within a main body case (2) and to which a pharmaceutical syringe (4) is removably mounted, a piston (5) provided movably with respect to the pharmaceutical syringe (4) mounted to the pharmaceutical syringe mounting portion (3), a drive mechanism (6) for driving the piston (5), a controller (7) that is electrically connected to the drive mechanism (6), a display section (35) that is connected to the controller (7), and an encoder (26) that is connected to the controller (7) and detects the amount of the pharmaceutical remaining inside the pharmaceutical syringe (4). The controller (7) displays a warning on the display section (35) recommending removal of the pharmaceutical syringe (4) from the pharmaceutical syringe mounting portion (3) when the presence of a pharmaceutical is detected by the encoder (26).Type: GrantFiled: July 25, 2017Date of Patent: December 25, 2018Assignees: PHC CORPORATION, JCR PHARMACEUTICALS CO., LTD.Inventors: Tsuguhiro Kondoh, Seiji Kikuchi, Takashi Hanada
-
Publication number: 20180283762Abstract: A movable workbench for performing work under low temperature, such as ?80° C. or below. The movable workbench includes: a worktable including a workspace forming member for providing a workspace for work at low temperature and a refrigerant-reservoir for containing a refrigerant, and disposed on a base with a moving member; the workspace forming member including side and bottom walls providing a workspace with an upper surface opening; the upper surface of the workspace being open on the upper side of the worktable; the refrigerant-reservoir accommodating the bottom wall of the workspace forming member so that a gas phase in the workspace is cooled when the refrigerant is provided in the refrigerant-reservoir and the bottom wall of the workspace forming member is subsequently cooled; and the moving member disposed on a bottom surface of the base so that the worktable is movable with the refrigerant-reservoir filled with the refrigerant.Type: ApplicationFiled: June 7, 2018Publication date: October 4, 2018Applicant: JCR PHARMACEUTICALS CO., LTD.Inventor: Minoru FUJII
-
Patent number: 10041039Abstract: Disclosed is a method for producing pluripotent stem cell-enriched human dental pulp-derived cells. The method is characterized in that it includes (a) culturing a dental pulp suspension in a feeder cells-culture vessel containing feeder cells whose proliferative ability is suppressed, on a membrane having micropores that can block passage of the feeder cells and supported in the feeder cells-culture vessel in a manner to prevent the lower side face thereof from contacting with the feeder cells, thereby preventing direct contact with the feeder cells, and, (b) a step for recovering the cells proliferating on the membrane.Type: GrantFiled: March 28, 2013Date of Patent: August 7, 2018Assignee: JCR PHARMACEUTICALS CO., LTD.Inventor: Kiwamu Imagawa
-
Publication number: 20180179291Abstract: Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.Type: ApplicationFiled: June 24, 2016Publication date: June 28, 2018Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20180171012Abstract: Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.Type: ApplicationFiled: June 24, 2016Publication date: June 21, 2018Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi